Drug
Iberdomide clinical trials
Also written CC-220 and BMS-986382.
- studies test it
- 41
- open now
- 13
- in phase 3
- 3
- first study started
- 2012
Keep track of what changes. Save the iberdomide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2022 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2019 | 1 |
| 2021 | 6 |
| 2022 | 8 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 23
- Phase 2
- 22
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 21
Celgene (11) · National Cancer Institute (NCI) (3) · Mayo Clinic (2) · Bristol-Myers Squibb (2) · Hoffmann-La Roche (2) · Celgene Corporation (2) · Memorial Sloan Kettering Cancer Center (1) · Pfizer (1)
Often tested with
Tested in the same studies.
Dexamethasone (13) · Daratumumab (4) · Elotuzumab (3) · Bortezomib (2) · Isatuximab (2) · Lenalidomide (2) · Carfilzomib (2) · Elranatamab (1)
Studies
Open first, then newest update. How each study uses iberdomide is read from its arms, and is right about nine times in ten.
Testing it · 41
- Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaRecruitingPhase 1National Cancer Institute (NCI)NCT06465316Written as Iberdomide
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecruitingPhase 1/2National Cancer Institute (NCI)NCT07437963Written as Iberdomide
- Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering MyelomaRecruitingPhase 2University College, LondonNCT06762769Written as Iberdomide
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as Iberdomide
- Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMMRecruitingPhase 1/2Omar Nadeem, MDNCT06518551Written as Iberdomide
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingPhase 1/2Hoffmann-La RocheNCT05583617Written as Iberdomide
- Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM PatientsRecruitingPhase 2Canadian Myeloma Research GroupNCT05272826Written as Iberdomide
- Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)Not yet recruitingEarly Phase 1Shambavi RichardNCT07727668Written as Iberdomide
- Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple MyelomaRecruitingPhase 2Barbara Ann Karmanos Cancer InstituteNCT06107738Written as Iberdomide
- NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomideRecruitingPhase 3PETHEMA FoundationNCT05558319Written as Iberdomide
- Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaRecruitingPhase 1/2Mayo ClinicNCT06785415Written as Iberdomide
- Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple MyelomaRecruitingPhase 2Emory UniversityNCT04776395Written as Iberdomide Hydrochloride
- Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Alfred Chung, MDNCT06348108Written as Iberdomide
- Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple MyelomaSuspendedPhase 2National Cancer Institute (NCI)NCT06179888Written as Iberdomide
- Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyActive, not recruitingPhase 1/2Mayo ClinicNCT05392946Written as Iberdomide
- Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple MyelomaSuspendedPhase 1/2Alliance for Clinical Trials in OncologyNCT06232044Written as Iberdomide
- Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)Active, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05354557Written as Iberdomide
- A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 3Bristol-Myers SquibbNCT05827016Written as Iberdomide
- A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)Active, not recruitingPhase 1PfizerNCT06215118Written as Iberdomide
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruitingPhase 1Hoffmann-La RocheNCT05169515Written as Iberdomide
See all 41 studies that test iberdomide →
Given in every arm · 12 — iberdomide is usual care beside what is tested
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMRecruitingPhase 3Dana-Farber Cancer InstituteNCT07624513Written as Iberdomide
- Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed MyelomaNot yet recruitingPhase 1/2Dana-Farber Cancer InstituteNCT07601100Written as Iberdomide
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06121843Written as Iberdomide
- Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1AbbVieNCT06896916Written as Iberdomide
- Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 2Benjamin T Diamond, MDNCT05896228Written as Iberdomide
- Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 3University of Heidelberg Medical CenterNCT06216158Written as Iberdomide
- Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple MyelomaTerminatedPhase 1CelgeneNCT04855136Written as CC-220
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomideActive, not recruitingPhase 1/2University of Alabama at BirminghamNCT05434689Written as Iberdomide
- Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.Active, not recruitingPhase 2PETHEMA FoundationNCT05527340Written as Iberdomide
- A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory LymphomasTerminatedPhase 1CelgeneNCT04464798Written as CC-220
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1/2CelgeneNCT03310619Written as CC-220
- Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaWithdrawnPhase 1/2CelgeneNCT04882163Written as CC-220
Codes
What other systems call iberdomide · ClinicalTrials.gg INT000809
- MeSH (NLM) C000624220iberdomideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8V66F27X44IBERDOMIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27271066iberdomideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C129048IberdomideOne source FDA
- DrugBank DB12101One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000624220 | iberdomide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8V66F27X44 | IBERDOMIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27271066 | iberdomide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C129048 | Iberdomide | One source FDA |
| DrugBank | DB12101 | — | One source Wikidata |
Also registered as iberdomide hydrochloride (UNII 79L3645KFI).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.